View in EDS

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Saved in:
Bibliographic Details
Title: A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Authors: Suder, A.1 anetasuder@hotmail.com, Ang, J.E.2 jooern.ang@icr.ac.uk, Kyle, F.1 fiona.kyle@gstt.nhs.uk, Harris, D.3 dean.harris@cdhb.health.nz, Rudman, S.1 sarah.rudman@gstt.nhs.uk, Kristeleit, R.3 r.kristeleit@ucl.ac.uk, Solca, F.4 flavio.solca@boehringer-ingelheim.com, Uttenreuther-Fischer, M.5 martina.uttenreuther-fischer@boehringer-ingelheim.com, Pemberton, K.6 karine.pemberton@boehringer-ingelheim.com, Pelling, K.7 katy.pelling@boehringer-ingelheim.com, Schnell, D.8 david.schnell@boehringer-ingelheim.com, de Bono, J.2 johann.de-Bono@icr.ac.uk, Spicer, J.9 james.spicer@kcl.ac.uk
Source: European Journal of Cancer. Nov2015, Vol. 51 Issue 16, p2275-2284. 10p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2015.07.041